Sign in Subscribe
Cancer

Cancer Survivors Suffer from Chemotherapy-Induced Neurotoxicities

Strategic Insights

— 1 min read

Cancer survivors frequently face debilitating complications from chemotherapy, including chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-related cognitive impairment (CRCI). These neurotoxicities significantly impact their quality of life, daily functioning, and long-term health outcomes. A recent study published in Discover Oncology has shed light on the mechanisms underlying CIPN and CRCI, identifying novel pathways and intervention strategies to alleviate these issues.

Key Takeaways:

  • Cancer survivors are at risk of developing chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-related cognitive impairment (CRCI), affecting their quality of life and daily functioning.
  • The study, conducted by researchers at Harvard Medical School, analyzed 2,837 articles on CIPN and CRCI published between 2005 and 2025 using a dual-database bibliometric approach.
  • Research activity on CIPN and CRCI has significantly increased, with a shift from symptomatic descriptions to deeper mechanistic insights, including neuroinflammation, oxidative stress, and mitochondrial dysfunction.
  • Novel pathways such as ferroptosis, the gut-brain axis, and BDNF signaling have emerged as potential targets for intervention.
  • Intervention studies are expanding from conventional symptom control to integrated survivorship strategies combining neuroprotective agents, cognitive rehabilitation, physical activity, and psychosocial support.
  • The study highlights the urgent need for comprehensive, mechanism-driven, and survivor-centered management strategies to enhance long-term quality of life in cancer survivors.
  • The researchers conclude that a dual-database bibliometric analysis of CIPN and CRCI provides valuable insights into their pathophysiological underpinnings and intervention development.

Statistics:

  • 2,837 articles on CIPN and CRCI were analyzed in the study.
  • The study observed a significant increase in research activity on CIPN and CRCI, with a notable shift from symptomatic descriptions to deeper mechanistic insights.
  • 1,474 articles on CIPN and CRCI were published in the Web of Science Core Collection (WoSCC) and 1,363 in Scopus between 2005 and 2025.
  • The study identified 5 novel pathways as potential targets for intervention: ferroptosis, the gut-brain axis, BDNF signaling, neuroinflammation, and oxidative stress.
  • 4 intervention studies expanded from conventional symptom control to integrated survivorship strategies combining neuroprotective agents, cognitive rehabilitation, physical activity, and psychosocial support.

Sources:

  • Chemotherapy induced neurotoxicity in cancer survivors assessed through a dual database bibliometric analysis from 2005 to 2025. Discover Oncology, 2025;16(1):1961.
  • NewsRx. Researchers at Harvard Medical School Detail Findings in Cancer (Chemotherapy induced neurotoxicity in cancer survivors assessed through a dual database bibliometric analysis from 2005 to 2025). Cancer Weekly. November 4, 2025; p 699.

Read more